Huntington's disease:: from huntingtin function and dysfunction to therapeutic strategies

被引:149
作者
Borrell-Pages, M. [1 ]
Zala, D. [1 ]
Humbert, S. [1 ]
Saudou, F. [1 ]
机构
[1] Inst Curie, CNRS, UMR 146, F-91405 Orsay, France
关键词
CAG expansion; polyglutamine; aggregation; intracellular transport; transcription; signal transduction; therapy;
D O I
10.1007/s00018-006-6242-0
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Huntington's disease (HD) is a neurodegenerative disorder that usually starts in middle age and is characterized by involuntary movements (chorea), personality changes and dementia, leading to death within 10-20 years. The defective gene in HD contains a trinucleotide CAG repeat expansion within its coding region that expresses a polyglutamine repeat in the protein huntingtin. Together with the characteristic formation of aggregates in HD, aberrant protein interactions and several post-translational modifications affect huntingtin during disease progression and lead to the dysfunction and death of selective neurons in the brains of patients. The exact molecular mechanisms,by which mutant huntingtin induces cell death are not completely understood but may involve the gain of new toxic functions and the loss of the beneficial properties of huntingtin. This review focuses on the cellular functions in which huntingtin is involved and how a better understanding of pathogenic pathways can lead to new therapeutic approaches.
引用
收藏
页码:2642 / 2660
页数:19
相关论文
共 253 条
  • [1] Neurotrophic factors in Huntington's disease
    Alberch, J
    Pérez-Navarro, E
    Canals, JM
    [J]. NGF AND RELATED MOLECULES IN HEALTH AND DISEASE, 2004, 146 : 195 - 229
  • [2] AMINOFF MJ, 1974, LANCET, V1, P107
  • [3] Creatine increases survival and delays motor symptoms in a transgenic animal model of Huntington's disease
    Andreassen, OA
    Dedeoglu, A
    Ferrante, RJ
    Jenkins, BG
    Ferrante, KL
    Thomas, M
    Friedlich, A
    Browne, SE
    Schilling, G
    Borchelt, DR
    Hersch, SM
    Ross, CA
    Beal, MF
    [J]. NEUROBIOLOGY OF DISEASE, 2001, 8 (03) : 479 - 491
  • [4] Mutant huntingtin alters MAPK signaling pathways in PC12 and striatal cells: ERK1/2 protects against mutant huntingtin-associated toxicity
    Apostol, BL
    Illes, K
    Pallos, J
    Bodai, L
    Wu, J
    Strand, A
    Schweitzer, ES
    Olson, JM
    Kazantsev, A
    Marsh, JL
    Thompson, LM
    [J]. HUMAN MOLECULAR GENETICS, 2006, 15 (02) : 273 - 285
  • [5] Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death
    Arrasate, M
    Mitra, S
    Schweitzer, ES
    Segal, MR
    Finkbeiner, S
    [J]. NATURE, 2004, 431 (7010) : 805 - 810
  • [6] Lentiviral vectors for treating and modeling human CNS disorders
    Azzouz, M
    Kingsman, SM
    Mazarakis, ND
    [J]. JOURNAL OF GENE MEDICINE, 2004, 6 (09) : 951 - 962
  • [7] Motor and cognitive improvements in patients with Huntington's disease after neural transplantation
    Bachoud-Lévi, A
    Rémy, P
    Nguyen, JP
    Brugières, P
    Lefaucheur, JP
    Bourdet, C
    Baudic, S
    Gaura, V
    Maison, P
    Haddad, B
    Boissé, MF
    Grandmougin, T
    Jény, R
    Bartolomeo, P
    Dalla Barba, G
    Degos, JD
    Lisovoski, F
    Ergis, AM
    Pailhous, E
    Cesaro, P
    Hantraye, P
    Peschanski, M
    [J]. LANCET, 2000, 356 (9246) : 1975 - 1979
  • [8] Effect of fetal neural transplants inpatients with Huntington's disease 6 years after surgery:: a long-term follow-up study
    Bachoud-Lévi, AC
    Gaura, V
    Brugières, P
    Lefaucheur, JP
    Boissé, MF
    Maison, P
    Baudic, S
    Ribeiro, MJ
    Bourdet, C
    Remy, P
    Cesaro, P
    Hantraye, P
    Peschanski, M
    [J]. LANCET NEUROLOGY, 2006, 5 (04) : 303 - 309
  • [9] Retest effects and cognitive decline in longitudinal follow-up of patients with early HD
    Bachoud-Lévi, AC
    Maison, P
    Bartolomeo, P
    Boissé, MF
    Dalla Barba, G
    Ergis, AM
    Baudic, S
    Degos, JD
    Cesaro, P
    Peschanski, M
    [J]. NEUROLOGY, 2001, 56 (08) : 1052 - 1058
  • [10] Safety and tolerability assessment of intrastriatal neural allografts in five patients with Huntington's disease
    Bachoud-Lévi, AC
    Bourdet, C
    Brugières, P
    Nguyen, JP
    Grandmougin, T
    Haddad, B
    Jény, R
    Bartolomeo, P
    Boissé, MF
    Dalla Barba, G
    Degos, JD
    Ergis, AM
    Lefaucheur, JP
    Lisovoski, F
    Pailhous, E
    Rémy, P
    Palfi, S
    Defer, GL
    Cesaro, P
    Hantraye, P
    Peschanski, M
    [J]. EXPERIMENTAL NEUROLOGY, 2000, 161 (01) : 194 - 202